지노믹트리
Financials
Valuation Metrics
지노믹트리's Market Cap is ₩2966B. At end of 2025 it was ₩6824B. Ranked #667 of 2,421 in KR market (top 28%), #277 of 1,640 on KOSDAQ (top 17%), #71 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 31%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 296.57B KRW | KR#667/2,421 Sec#71/231 |
| Revenue | 2.95B KRW | KR#2,373/2,421 Sec#208/231 |
| Net Income | -9.19B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 124.41B KRW | KR#1,627/2,421 Sec#129/231 |
| Net Assets | 121.93B KRW | KR#1,282/2,421 Sec#99/231 |
| Employees | 79 | KR#1,817/2,421 Sec#154/231 |
| Value | ||
| P/B | 2.43x | KR#2,027/2,421 Sec#155/231 |
| P/S | 100.66x | KR#2,391/2,421 Sec#208/231 |
| FCF Yield | -4.36% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -7.54% | KR#1,878/2,421 Sec#137/231 |
| ROA | -7.39% | KR#2,028/2,421 Sec#148/231 |
| Op. Margin | -398.40% | KR#2,360/2,421 Sec#200/231 |
| Revenue Growth | -17.13% | KR#2,088/2,421 Sec#190/231 |
| Financial Health | ||
| Debt Ratio | 2.03% | KR#9/2,421 Sec#4/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -12.92B KRW | KR#1,781/2,421 Sec#158/231 |
| Cash | 17.47B KRW | KR#1,325/2,421 Sec#103/231 |
| Current Ratio | 60.85x | KR#3/2,421 Sec#1/231 |
| Performance | ||
| 1Y Return | -48.58% | KR#2,029/2,421 Sec#182/231 |
| 1M Return | 1.10% | KR#1,104/2,421 Sec#82/231 |
| From 52W High | -64.17% | KR#2,009/2,421 Sec#162/231 |
| 1Y MDD | -68.66% | KR#1,930/2,421 Sec#165/231 |
| Trading | ||
| Volume | 462,006 shares | KR#251/2,421 Sec#14/231 |
| Trading Value | 5.41B KRW | KR#352/2,421 Sec#33/231 |
| Foreign Own. | 2.71% | KR#1,379/2,421 Sec#127/231 |
| Per Share | ||
| EPS | -370 KRW | KR—/2,421 Sec—/231 |
| BPS | 4,905 KRW | KR#1,507/2,421 Sec#108/231 |
Company Info
Genomictree was established in 2000 as a specialized enterprise for cancer auxiliary diagnosis, listed on KONEX, and then transferred its listing to KOSDAQ in 2019. Headquartered in Yuseong-gu, Daejeon, it possesses DNA methylation biomarker discovery and ultra-sensitive detection technology, developing and commercializing body fluid-based non-invasive early cancer diagnosis products. Its flagship product, EarlyTect-C, received Ministry of Food and Drug Safety approval in 2018 and is sold in domestic hospitals and clinics, with technology transfer completed and product approval applications underway in China.